Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Non-Current Receivables (2016 - 2022)

Historic Non-Current Receivables for Avadel Pharmaceuticals (AVDL) over the last 11 years, with Q3 2022 value amounting to $1.1 million.

  • Avadel Pharmaceuticals' Non-Current Receivables rose 1831.43% to $1.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.1 million, marking a year-over-year increase of 1831.43%. This contributed to the annual value of $1.2 million for FY2021, which is 6444.12% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Non-Current Receivables of $1.1 million as of Q3 2022, which was up 1831.43% from $1.2 million recorded in Q2 2022.
  • Avadel Pharmaceuticals' 5-year Non-Current Receivables high stood at $7.8 million for Q2 2019, and its period low was $961000.0 during Q3 2021.
  • For the 5-year period, Avadel Pharmaceuticals' Non-Current Receivables averaged around $4.5 million, with its median value being $5.9 million (2018).
  • Its Non-Current Receivables has fluctuated over the past 5 years, first soared by 14636.89% in 2018, then plummeted by 8465.74% in 2021.
  • Over the past 5 years, Avadel Pharmaceuticals' Non-Current Receivables (Quarter) stood at $7.3 million in 2018, then dropped by 13.06% to $6.3 million in 2019, then tumbled by 45.51% to $3.4 million in 2020, then tumbled by 64.44% to $1.2 million in 2021, then fell by 7.18% to $1.1 million in 2022.
  • Its last three reported values are $1.1 million in Q3 2022, $1.2 million for Q2 2022, and $1.2 million during Q1 2022.